Summary

Eligibility
for people ages 3 months to 18 years (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Jeffrey Fineman, MD

Description

Summary

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better World Health Organization (WHO) functional class at 12 months after initiation of PAH treatment than therapy with sildenafil alone.

Official Title

Kids MoD PAH Trial: Mono- vs. Duo-Therapy for Pediatric Pulmonary Arterial Hypertension

Details

Keywords

Pediatric Pulmonary Hypertension, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Bosentan, Sildenafil Citrate, Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan

Eligibility

Locations

  • The Regents of the UCSF accepting new patients
    San Francisco California 94158 United States
  • University of Utah Hospital accepting new patients
    Salt Lake City Utah 84132 United States

Lead Scientist at UCSF

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Johns Hopkins University
ID
NCT04039464
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated